Gracell, FutureGen to develop engineered immunotherapies

By The Science Advisory Board staff writers

August 18, 2021 -- Gracell Biotechnologies has signed an exclusive licensing agreement with FutureGen Biopharm to develop engineered immune cell therapies targeting Claudin 18.2 (CLDN18.2) in solid tumors.

The companies will develop, manufacture, and commercialize new immune cell therapies for patients with CLDN18.2-positive cancers using Gracell's immune cell therapy experience and FutureGen's fully human CLDN18.2 antibodies.

"The fine-tuned affinity of [the] antibody for CAR-T application may eliminate CLDN18.2 positive tumor cells more specifically with better safety profile," stated FutureGen CEO Dr. Zhaoyu Jin in a release.

Under the agreement, FutureGen will receive an upfront payment and will be eligible to receive additional payments based on the achievement of nonclinical validation, clinical development, and commercialization milestones, in addition to low-single-digit royalties.

Gracell advances study, signs cell therapy deal
Gracell Biotechnologies has moved ahead with a cancer treatment research study and has signed a deal to manufacture its cell therapy products.
Gracell secures funding to advance CAR T therapies
Gracell Biotechnologies has secured $100 million in series C funding to expand its chimeric antigen receptor (CAR) T-cell therapies.

Copyright © 2021

International Society for Cell and Gene Therapy Annual Meeting
May 4 - June 7
San Francisco, California United States
Interphex 2022 Conference
May 24-26
New York, New York United States
American Society for Mass Spectrometry Annual Conference
June 5-9
Minneapolis, Minnesota United States
American Society for Microbiology Microbe Meeting
June 9-13
District of Columbia United States
HPLC 2022
June 18-23
San Diego, California United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter